Here are the key details: Start date: July 1, 2026 End date: December 31, 2027 (unless extended by Congress) Eligible medications: FDA-approved anti-obesity medications, including Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) Patient cost: Flat $50 per month copay Deductible: Waived - the Part D deductible does not apply to medications obtained through this program Prior authorization: Required by most Part D plans, but criteria are standardized under the program The bridge structure is important to understand
Attending these appointments is key to achieving your weight loss goals safely and effectively
Based on your needs, our medical team prepares a custom L-glutathione dose, either as a quick IV push or combined with your IV therapy drip
Documentation should not be interpreted as confirmation that every batch has been independently tested
We offer compassionate care that respects every individuals unique journey by combining advanced medical science with modern technology
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class and is studied for its effects on metabolic signaling